Mymetics Corp (MYMX)

[Work Harder]

Gerald Voss

17

TuBerculosis Vaccine Initiative (TBVI), GHF4+6W Lelystad, the Netherlands. Electronic address:

https://pubmed.ncbi.nlm.nih.gov/34489131/

https://pubmed.ncbi.nlm.nih.gov/?term=Voss%20G%5BAuthor%5D&cauthor=true&cauthor_uid=21987658

Dr. Gerald Voss is the Scientific Director of the TuBerculosis Vaccine Initiative (TBVI, Lelystad, The Netherlands) and the Executive Director of SciPeo Sprl, Science & People, a life sciences and coaching consultancy.

Gerald recently served as the Interim Director of the Global HIV Vaccine Enterprise (New York, USA) and led the organization through a merger with the International AIDS Society.

He was previously with GSK vaccines (Rixensart, Belgium), leading the R&D portfolio for Diseases of the Developing World. During his tenure, Dr. Voss established and lead Product Development Partnerships in HIV, TB and malaria with the International AIDS Vaccine Initiative, Aeras, the Malaria Vaccine initiative and the Bill&Melinda Gates Foundation.

Gerald holds a Ph.D. in Biology from Goettingen University (Germany) and received his post-doctoral training at Harvard Medical School (Boston, USA).

https://www.tbvi.eu/team/dr-gerald-voss-2/

https://be.linkedin.com/in/gerald-voss-42597b32?challengeId=AQELiJLTHcVbjQAAAX_MSGWSGusOeAQffmVuP8CCEFcZKdlfsXVG8A63370leeNOqK-DGx0B0swRaYeqtf4ytufsmuAWakjOKg&submissionId=622dcf99-db4a-e016-78ad-94cd78966401

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167840863

Ronnie, instead of being the coach, you should reach out to this guy

LOL